Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference
http://finance.yahoo.com/news/rxi-pharmaceuticals-present-dawson-james-110200077.html
I'm thinking the company wants to release the 5 doses RXI-109 against untreated before then. Positive phase 2a results should send the share price higher. Either that or possible partnership with collagenese or Tyrosinase might play out as well. GL to all of us in this!
short sellers
RXi Pharmaceuticals to Present at the 15th Annual Biotech in Europe Forum for Global Partnering and Investment Conference
http://finance.yahoo.com/news/rxi-pharmaceuticals-present-15th-annual-110200710.html
Rxi CEO will be presenting at this Biotech Forum in Switzerland
Title: 15th Annual Biotech in Europe Forum for Global Partnering & Investment
Date: 09/29/2015 - 09/30/2015
Basel, Switzerland
About the 15th Annual Biotech in Europe Forum
The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 700+ delegates and 120+ presenting companies.
The 15th Annual is held for the second time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one- to- one meetings as well as significant exhibition space. The Programme will feature twelve plenary panels/workshops covering BD & Licensing in the main therapeutic areas.
The Meeting will provide a number of networking opportunities via our online 1-2-1 meeting system which allows you to pre-book meetings with all the attendees. We expect more than 2000 meetings to take place throughout the 2 days
As long as initiatives go yes. But the main one is the phase 2a scar results Mid October, about a month from now. We will see if the increased doses of RXI-109 improved the results. If the results/pictures are good we could see a nice run after that.
You didn't even know that Tang Capital was sold out of all preferred shares, and all out of common shares. Sounds to me like you do need help investing. Your words not mine:
"Who in their right mind pumps a stock when everyone and their dog knows there's a massive roadblock due to warrant guys at .40 who will gladly dump here at .50 for a great profit ? And who in their right mind in the contents of their pump says "the market makers have taken control of the stock" ? ROTFLOL. No legitimate analyst would EVER EVER EVER say that.The people that have taken control of the stock are the warrant guys and the guys who got shares converted from the preferred. This thing will be back below .40 in a flash IMO. Too early to pump this thing right now with the pressure. And you'd better believe that the frontloaders of the pump are very aware of the warrant guys who will dump right here and if you think for one second the frontloaders aren't taking profit as well, think again, no matter what they'll tell you."
Yah I'm not worried all that matters is the phase 2a results of RXI-109 in hypertrophic scars in Mid-october. If good stock will easily pull over $1 or more regardless of warrants.
I agree this could continue its run up , sellers are exhausted, shorts will probably be covering soon.
Again you haven't done your DD. The preferred guy was TAng CApital who no longer has preferred shares. They had 1.7 million commmon shares left which they sold out. Their are 0 preferred shares right now you can even look it up yourself. Their are warrants only of course that's it. Again had you done proper DD you would have known that.
If you were an informed biotech investor you would know that the move now is for the scar results for RXI-109 phase 2a which is set to be released Mid October 2015. Had you done proper DD you would have known that.
More news this morning
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Ocular Indications
http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200843.html
Rxi already told investors that they will have updated scar results in Mid-October 2015. They will be 5 doses of RXI-109 over 3 months compared to untreated. If better pictures this will easily go over $1
Totally wrong. Everyone is totally way off. Rxi already told you that they are expecting updated scar results for study 1402 hypertrophic scars.
It will be 5 doses over 3 months , instead of the first time being 3 doses over 3 months.
If the updated pictures show further scar reduction compared to the previous pictures this will easily go over $1.
I think so too! This is pretty big news. In addition to no FDA approved drug for scarring. There is no FDA approved product for retinal scarring of macular degeneration. There are drugs to treat the neovascular compoment of Wet AMD but none that deal with the scarring. Rxi bags another unmet medical need in the bag. Holing long-term on this one.
RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109
Zoriden you were right news came
FDA approves IND for RXI-109 in retinal scarring of advanced macular degeneration patients
http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-advancements-ophthalmology-110200017.html
New Seeking alpha Article on Anavex
Why Anavex Is Leading The Race Against Other Pharma To Help Alzheimer's Patients
http://seekingalpha.com/article/3470716-why-anavex-is-leading-the-race-against-other-pharma-to-help-alzheimers-patients
That they did, but that is the past.
Now all that matters is the phase 2 scar results update we will see in October 2015.
It will be 5 doses of RXI-109 on one side against untreated on the other side.
Considering the 3 doses RXI-109 look pretty good compared to placebo slide 11 of Presentation:
http://investors.rxipharma.com/Cache/1500072639.PDF?Y=&O=PDF&D=&fid=1500072639&T=&iid=4418218
The new picture results will be with 5 doses. But the trial itself is running all the way through to 6 doses. I believe the company is gonna attempt to show early good data to boost the share price before the November 5, 2015 deadline to regain compliance. With good pictures that will be easy.
Don't look at that info use the Nasdaq website its more accurate for that.
Tang is gone, he even sold out all his shares
Look at the updated ownership on RXII on website. It now shows as of June 30, 2015 Broadfin capital increased their stake in RXII from 1.1 million shares to 6.2 million shares now.
That's an increase of 5 million shares. Kevin Kotler of Broadfin Capital is smart and he know the long-term value of the company despite the decline in share price by Tang Capital converting shares.
Here is link for Broadfin capital ownership
http://investors.rxipharma.com/institutionalownership.aspx?iid=4418218
They could potentially start phase 2 trial for Warts before end of 2015 or start the phase 1/2 retinal scar trial before then.
There is also another possibility if Geert has a partnership lined up by then or is currently in talks with pharmaceutical companies to make a partnership with upfront money.
More likely than not results would have to be released in October 2015 which is the best chance. Of course though the share price could rise in anticipation of said results that's possible too.
On the CC they said they are already speaking to the IRB about setting up clinical sites and stuff. They are getting ready to go, they just need the green light from the FDA to start recruiting the patients.
If anyone listened to the CC or has seen the transcript you would know a few nice things about this trial that will be known as 1501.
1. It will be on advanced patients with macular degeneration. Not new mac d patients or mid stage ones, but advanced stage macular degeneration patients
2. The trials are gonna be run under the leadership of Compachiaro at John Hopkins wilmer Eye Institute which is the best top notch eye institute in the United states. Not only that but Dr. Compachiaro and his lab were responsible for discovering that VEGF blocks the inhibition of macular degeneration and currently serves on the scientific advisory board for RXII
3. The Filing of the IND was end of July so trial should be good to start probably September/October. Company says before end of 2015.
4. People don't understand the implication of this trial. If patients are also taking an anti VEGF and RXI-109 shows good reduction of the scars then Rxi can be approached by Regeneron, Roche for possible partnerships with Eylea and Lucentis.
We got a lot of information today.
1.) RXI-109 IND was filed around few weeks ago. That remains on track!
2.) RXI-109 for retinal scarring though can skip a phase 1 trial and go straight to phase 1/2 trial - multidosing because RXI-109 has already been tested for safety in the skin
3.) There will be scar result data for 3 months and 6 months of study 1402 by October 2015. The results will be patients receiving up to 5 doses over the proliferation phase just barely meeting the 6th dose. I assume company is getting the data out by then to show results before November 3, 2015 deadline with Nasdaq.
4.) Samcyprone for warts will start a trial before end of the year in 2015
5.) CEO is working on business development with other biotechs that expressed interest
6.) CEO didn't specifically say, but someone on questions asked how the share price would increase. It is possible where Rxi could have a biotech or big pharma invest in RXII shares to increase share price. Again speculation but I read in between the lines on that one.
7.) Any other catalysts that may develop
I personally think that the CC was great and look forward to more news in the coming months!
Basically Rxi submitted the IND and FDA now has 30 day review period to review data and if all is in order Rxi will start phase 1/2 retinal scarring macular degeneration trial before the end of 2015.
RXi Pharmaceuticals Reports Second Quarter 2015 Financial Results and Business Highlights
http://finance.yahoo.com/news/rxi-pharmaceuticals-reports-second-quarter-110200530.html
I would hope that there is at least some type of update the company hasn't released any substantial news on the pipeline for months. Hopefully tomorrow we hear some type of news other than financial results.
Good Article I found about Rxi catalysts
Rxi Pharmaceuticals Should Be On Your Radar Before Major Catalysts
http://www.biotechpicklist.com/rxi-pharmaceuticals-should-be-on-your-radar-before-major-catalysts/
Yep Short sellers. Shouldn't stay down for long. News of RXI-109 IND in retinal scarring macular degeneration should move it up.
I think the company is waiting for August to release some news. Reason being is they did that last year in 2014. When I spoke to IR they said that they don't like to release news during the summer cause money managers etc. are on vacation. Maybe now that it is August and we are nearing the CC we will get some updates on the clinical trials and head higher in RXII
I agree once news hits in a few weeks RXII will be edging higher, and people will be chasing it up a lot higher than current share price.
I have been telling people to abandon ship like 2 years ago. Despite looking at the business model you gotta look at the red flag.
An IND is a an application for a new drug to be entered into phase 1 testing. A biotechnology company must submit animal safety study, and other protocols.
A typical IND only takes 3 to 6 months to confer with the FDA. The big red flag here is that an IND has been in process for 2 years or more which is a huge red flag.
Actually here is the press release for the IND for Hemaxellerate being filed back in Feb 5, 2013. So that means for 2 years and 5 months an IND has been submitted but nothing done? That's fishy folks do not be suckered here.
http://www.marketwired.com/press-release/regen-biopharma-files-investigational-new-drug-ind-application-with-fda-on-hemaxellerate-pinksheets-bmsn-1753381.htm
These types of stocks trade on pinksheets for a reason they don't have to be legit in their SEC filings like companies that trade on the NASDAQ or NYSE.
RXII will get above $1 easily.
To answer everyone's question about how long Rxi has to get share price above $1 per share?
Rxi has until November 5, 2015. With the upcoming catalysts that easily attainable.
Especially after what I saw today rxi will move on its own. Dropped down today to -10% and closed HOD up 5.24%. To me that shows buying strength
Do you see that 91,400 volume bid at .53 cents per share RXII seems someone wants to support it at that price. That's a big bid
We need more volume but all looks good so far. If we have news this thing would sky rocket. Hopefully we hear something about the IND for RXI-109 in retinal scarring macular degeneration soon.
That's not right. It hasn't been updated yet because the shares outstanding now for RXII is 58 mil shares outstanding.
Exactly right. Look at Tekmira and Arrowhead they had problems with their trials and they have about $700 mil to $300 mil market cap.
Rxi only has $30 mil market cap. This is way undervalued.
IMO though Rxi will probably be partnered out with a big pharma for Pulmonary Fibrosis or Liver fibrosis. Those are scarring of the lungs and liver respectively.
Remember Roche Bought Intermine for $8 Billion just for pulmonary Fibrosis drug.
Scarring anywhere from $2 billion to $5 billion
macular degeneration $3 billion to $4 billion
CNS disorders depends:
If Rxi goes for SMA -- Spinal muscular Atrophy -- $5 billion
if Rxi branches out dermatology to Chronic Wounds $15 billion - $18 billion
It just depends what they choose for the Tyrosinase and collagenese compounds. -- chronic wounds falls under collagenese target if they choose it